Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | June 13, 2019 | June 14, 2019 |
| INCYTE CORPINCY · Entity 3182 | Director | September 30, 2026 | October 03, 2026 |
| Karuna Therapeutics, Inc.KRTX · Entity 92934 | Director | August 12, 2020 | August 14, 2020 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,148 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 43,148 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
BELLICUM PHARMACEUTICALS, INC
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2029-06-12 | Direct | 25,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date.
INCYTE CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,225 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 206 · Balance 23,225 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
F2: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Karuna Therapeutics, Inc.
Report date August 12, 2020 · Filed August 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,163 |
Reported balance
After 2020-08-12 transaction · row 1
1 source rowRow 1 · 2020-08-12 · Sale · Disposed 10,000 · Balance 55,163 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,750 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 9,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2022 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · nonDerivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:44 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000061 · wf-form4_165307946306515.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:44 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000061 · wf-form4_165307946306515.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 240 | $79.42 | $19,060.80 |
DisclosureSEC source: 0001209191-22-022292 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,572 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:17 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 253 | $73.40 | $18,570.20 |
DisclosureSEC source: 0001209191-22-000712 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:36 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 237 | $68.78 | $16,300.86 |
DisclosureSEC source: 0001209191-21-058993 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,079 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 11:32 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 208 | $84.13 | $17,499.04 |
DisclosureSEC source: 0001209191-21-044648 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,842 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043041 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391 Underlying: Common Stock · 6,391 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,637 | $0.00 Strike: $24.88 | $0.00 |
DisclosureSEC source: 0001209191-21-043041 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 Underlying: Common Stock · 11,637 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · derivative · entry 4 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 18:08 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001169245-21-000063 · wf-form4_162284452303145.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| May 26, 2021 Filed May 28, 2021 11:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,010 | $0.00 Strike: $83.16 | $0.00 |
DisclosureSEC source: 0001209191-21-036407 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| May 26, 2021 Filed May 28, 2021 11:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036407 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 21:20 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 219 | $81.27 | $17,798.13 |
DisclosureSEC source: 0001209191-21-024163 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,711 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 207 | $86.98 | $18,004.86 |
DisclosureSEC source: 0001209191-21-001236 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,492 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 15:53 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 6,000 | $4.12 | $24,720.00 |
DisclosureSEC source: 0001169245-20-000109 · wf-form4_160711520255981.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.11 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 187 | $89.74 | $16,781.38 |
DisclosureSEC source: 0001209191-20-052642 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:13 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 10,000 | $83.32 | $833,200.00 |
DisclosureSEC source: 0001593968-20-001750 · primary_01.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,163 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 13, 2020 Filed Jul 13, 2020 20:48 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 10,000 | $93.40 | $934,000.00 |
DisclosureSEC source: 0001593968-20-001630 · primary_01.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,163 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 152 | $103.97 | $15,803.44 |
DisclosureSEC source: 0001209191-20-039796 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038978 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Underlying: Common Stock · 3,059 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 5,579 | $0.00 Strike: $52.73 | $0.00 |
DisclosureSEC source: 0001209191-20-038978 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579 Underlying: Common Stock · 5,579 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 21:20 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 30,000 | $91.79 | $2,753,700.00 |
DisclosureSEC source: 0001593968-20-001466 · primary_01.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,163 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:34 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $97.59 | $0.00 |
DisclosureSEC source: 0001593968-20-001420 · primary_01.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 4, 2021, and (ii) the 2021 annual meeting of the Issuer's stockholders. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 18:55 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001169245-20-000061 · wf-form4_159139767242006.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2021 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:32 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,514 | $0.00 Strike: $98.68 | $0.00 |
DisclosureSEC source: 0001209191-20-032603 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:32 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032603 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 22:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 202 | $73.23 | $14,792.46 |
DisclosureSEC source: 0001209191-20-022768 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 462 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 00:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantCommon Stock | 105,163 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007992 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,163 Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option · Derivative | 4,360 | $0.00 Strike: $91.31 | $0.00 |
DisclosureSEC source: 0001209191-19-061321 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,360 Underlying: Common Stock · 4,360 shares Expires 2029-12-16 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061321 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 23:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantStock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-19-018727 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 27, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 21:10 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $25.24 | $0.00 |
DisclosureSEC source: 0001209191-19-039523 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-06-26 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001358403-19-000096 · wf-form4_156054271037497.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| May 09, 2019 Filed May 13, 2019 16:37 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 4,583 | $0.00 Strike: $13.23 | $0.00 |
DisclosureSEC source: 0001209191-19-029356 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Underlying: Common Stock · 4,583 shares Expires 2029-05-09 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the date of the 2020 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 16:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantEmployee Stock Option (right to buy) · Derivative | 68,966 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-18-062943 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,966 Underlying: Common Stock · 68,966 shares Expires 2028-12-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months on the same day of the month as the Initial Vesting Date, subject to the reporting person's continued service through each such date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:30 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001358403-18-000060 · wf-form4_152935382297879.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · Not disclosed shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2019 Annual Meeting of stockholders. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001415889-18-000912 · form4-06082018_020641.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F2 · security: Annual committee grant. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001415889-18-000912 · form4-06082018_020641.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 3,166 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001358403-18-000027 · wf-form4_151933343834183.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,166 Underlying: Common Stock · 3,166 shares Expires 2028-02-19 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal installments on each of March 20, April 20, May 20, and June 14, 2018, and will vest in full upon a change in control. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001358403-18-000027 · wf-form4_151933343834183.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments from the date of grant, and will vest in full upon a change in control. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 21:21 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001415889-17-001228 · form4-07192017_020747.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:14 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000990 · form4-06142017_030611.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.